The stock of Cempra Inc (NASDAQ:CEMP) is a huge mover today! About 286,637 shares traded hands. Cempra Inc (NASDAQ:CEMP) has risen 20.83% since March 7, 2016 and is uptrending. It has outperformed by 13.24% the S&P500.
The move comes after 9 months positive chart setup for the $1.22 billion company. It was reported on Oct, 10 by Barchart.com. We have $30.69 PT which if reached, will make NASDAQ:CEMP worth $390.40M more.
Analysts await Cempra Inc (NASDAQ:CEMP) to report earnings on October, 27. They expect $-0.64 EPS, down 1.59% or $0.01 from last year’s $-0.63 per share. After $-0.51 actual EPS reported by Cempra Inc for the previous quarter, Wall Street now forecasts 25.49% negative EPS growth.
Cempra Inc (NASDAQ:CEMP) Ratings Coverage
Out of 9 analysts covering Cempra (NASDAQ:CEMP), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. Cempra has been the topic of 13 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The rating was initiated by Leerink Swann on Tuesday, October 13 with “Mkt Perform”. Janney Capital initiated Cempra Inc (NASDAQ:CEMP) on Friday, December 11 with “Buy” rating. The rating was initiated by Raymond James with “Outperform” on Tuesday, September 13. Morgan Stanley initiated Cempra Inc (NASDAQ:CEMP) rating on Thursday, August 13. Morgan Stanley has “Equal-Weight” rating and $40 price target. The company was maintained on Friday, October 23 by Stifel Nicolaus. The firm has “Buy” rating by Jefferies given on Tuesday, August 2. The company was maintained on Friday, June 24 by Stifel Nicolaus. Morgan Stanley upgraded it to “Overweight” rating and $38 target price in Monday, November 16 report. The stock has “Buy” rating given by Roth Capital on Tuesday, June 7. The firm earned “Buy” rating on Thursday, July 30 by Needham.
According to Zacks Investment Research, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina.”
Insitutional Activity: The institutional sentiment increased to 2.27 in Q2 2016. Its up 0.72, from 1.55 in 2016Q1. The ratio improved, as 10 funds sold all Cempra Inc shares owned while 23 reduced positions. 14 funds bought stakes while 61 increased positions. They now own 39.80 million shares or 3.16% more from 38.58 million shares in 2016Q1.
Fmr Limited Company owns 7.23M shares or 0.02% of their US portfolio. Levin Cap Strategies Limited Partnership reported 1.43 million shares or 0.42% of all its holdings. Blackrock Inc has 4,573 shares for 0% of their US portfolio. Moreover, Portolan Cap Mgmt Limited Com has 0.7% invested in Cempra Inc (NASDAQ:CEMP) for 295,575 shares. Belmont Glob Advisors accumulated 15,000 shares or 0.24% of the stock. Landscape Cap Limited Liability Co has invested 0.22% of its portfolio in Cempra Inc (NASDAQ:CEMP). Moreover, Columbia Prns L L C Mngmt has 0.31% invested in Cempra Inc (NASDAQ:CEMP) for 252,998 shares. Axa accumulated 416,319 shares or 0.03% of the stock. Franklin Street Advsr Nc has 0.17% invested in the company for 54,100 shares. Legal And General Gru Public Ltd Com accumulated 7,102 shares or 0% of the stock. Pennsylvania reported 70,158 shares or 0.09% of all its holdings. Da Davidson And last reported 0% of its portfolio in the stock. Sabby Limited Liability Company holds 0.06% of its portfolio in Cempra Inc (NASDAQ:CEMP) for 64,065 shares. Ontario Teachers Pension Plan Board, a Ontario – Canada-based fund reported 854,564 shares. Invesco holds 0% of its portfolio in Cempra Inc (NASDAQ:CEMP) for 422,216 shares.
CEMP Company Profile
Cempra, Inc., incorporated on May 16, 2008, is a clinical-stage pharmaceutical company. The Firm is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. The Firm also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.